UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract P5-11-07: Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-11-07

2017

Volltextzugriff (PDF)

Simultaneous determination of cyclodol and diprazin by thin layer chromatography and high performance liquid chromatography

Georgian medical news, 2009-11 (176), p.66

2009

Volltextzugriff (PDF)

Abstract P5-11-08: Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-11-08

2017

Volltextzugriff (PDF)

Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-11-09

2017

Volltextzugriff (PDF)

Investigation of conjugation and metabolism of propofol with the method of high performance liquid chromatography

Georgian medical news, 2009-04 (169), p.98-100

2009

Volltextzugriff (PDF)

Using of chromatographical methods to study stability, pharmacokinetics and metabolism of propofol (review)

Georgian medical news, 2009-05 (170), p.95-100

2009

Volltextzugriff (PDF)

New methods of chemical and toxicological study of clonidine (Clophelinum)

Georgian medical news, 2007-09 (150), p.46

2007

Volltextzugriff (PDF)

Clinical pharmacokinetics and pharmacodynamics of quinidine

Kardiologiia, 1983-08, Vol.23 (8), p.107

1983

Volltextzugriff (PDF)

Immunomodulators of plant origin (review)

Pharmaceutical chemistry journal, 1993-08, Vol.27 (8), p.589-595

1993

Volltextzugriff (PDF)

Clinical significance of genetically determined polymodality of the distribution of quinidine elimination rates

Kardiologiia, 1988-02, Vol.28 (2), p.56

1988

Volltextzugriff (PDF)

Method of analysis of novocainamide and its main metabolite —N-acetyl derivative — In blood serum using highly efficient liquid chromatography

Pharmaceutical chemistry journal, 1983-07, Vol.17 (7), p.512-515

1983

Volltextzugriff (PDF)

Epigenetic inheritance of diet-induced and sperm-borne mitochondrial RNAs

Nature (London), 2024-06, Vol.630 (8017), p.720-727

2024

Volltextzugriff (PDF)

1853P Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy

Annals of oncology, 2024-09, Vol.35, p.S1092-S1092

2024

Volltextzugriff (PDF)

49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S70-S71

2023

Volltextzugriff (PDF)

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-11, Vol.33, p.S1567-S1568

2022

Volltextzugriff (PDF)

954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

Annals of oncology, 2022-09, Vol.33, p.S983-S984

2022

Volltextzugriff (PDF)

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9028-9028

2023

Volltextzugriff (PDF)

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Annals of oncology, 2021-12, Vol.32, p.S1414

2021

Volltextzugriff (PDF)

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-09, Vol.32, p.S1328-S1328

2021

Volltextzugriff (PDF)

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

ESMO open, 2024-03, Vol.9, p.102643, Article 102643

2024

Volltextzugriff (PDF)

75P Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation

Immuno-oncology technology, 2023-12, Vol.20, p.100547, Article 100547

2023

Volltextzugriff (PDF)

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101493, Article 101493

2023

Volltextzugriff (PDF)

Cloud-point preconcentration of fulvic and humic acids

Talanta (Oxford), 1999-02, Vol.48 (2), p.409-413

1999

Volltextzugriff (PDF)

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

Immuno-oncology technology, 2022-12, Vol.16, p.100234, Article 100234

2022

Volltextzugriff (PDF)

PC71 IODINE DEFICIENCY IN GEORGIA

Journal of pediatric gastroenterology and nutrition, 2004-06, Vol.39 (S1), p.S539-S539

2004

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(33)
Russisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(9)
Adult
(4)
Female
(4)
Male
(4)
Science & Technology
(4)
Animals
(3)
Middle Aged
(3)
Anesthetics, Intravenous - Pharmacokinetics
(2)
Chemistry
(2)
Dispersion
(2)
Fluorescence
(2)
Laser Excitation
(2)
Metabolic Clearance Rate
(2)
Multidisciplinary Sciences
(2)
Propofol - Pharmacokinetics
(2)
Quinidine - Administration & Dosage
(2)
Scattering
(2)
Science & Technology - Other Topics
(2)
Technology
(2)
Time Factors
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Abstract P5-11-07: Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Simultaneous determination of cyclodol and diprazin by thin layer chromatography and high performance liquid chromatography

Abstract P5-11-08: Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study

Investigation of conjugation and metabolism of propofol with the method of high performance liquid chromatography

Using of chromatographical methods to study stability, pharmacokinetics and metabolism of propofol (review)

New methods of chemical and toxicological study of clonidine (Clophelinum)

Clinical pharmacokinetics and pharmacodynamics of quinidine

Immunomodulators of plant origin (review)

Clinical significance of genetically determined polymodality of the distribution of quinidine elimination rates

Method of analysis of novocainamide and its main metabolite —N-acetyl derivative — In blood serum using highly efficient liquid chromatography

Epigenetic inheritance of diet-induced and sperm-borne mitochondrial RNAs

1853P Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy

49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

75P Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation

154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer

Cloud-point preconcentration of fulvic and humic acids

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

PC71 IODINE DEFICIENCY IN GEORGIA

Suchergebnisse filtern